solute carrier family 17 member 7Genealiases: BNPI · VGLUT1
Q-omics provides the consensus-scored SLC17A7 profile across patient tissues and cancer cell-line models. SLC17A7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC17A7 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, SLC17A7 RNA expression shows 17,245 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, THCA, and GBM as cancer lineages where SLC17A7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC17A7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC17A7 survival associations across molecular data types. SLC17A7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC17A7 RNA expression–survival associations across cancer types. High SLC17A7 expression shows unfavorable associations in ACC, KIRP, MESO, KIRC and OV, but favorable associations in ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC17A7 RNA expression.
This table summarizes SLC17A7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SLC17A7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC17A7 shows lower tumor expression in THCA, COAD, KIRC, KICH, BRCA and BLCA. The THCA box plot shows higher SLC17A7 RNA expression in normal versus tumor tissue (log2 FC = −1.200, t-test p < 0.001).
This table shows molecular features associated with SLC17A7 in patient tissues and cancer cell lines. In patient samples, SLC17A7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC17A7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
